Member Info for Bella6532

Shoot...should read...Don't assume the fundraiser means there isn't a deal or deals being worked on.

Knowing what we knew at the time, the fundraise miggt have seemed a bit early..however, it may also be about what we don't know.

Also...Receivables can't be taken into account when Going Concern is calculated...only payables. So even if a deal might be in the works with a huge up front payment...this cannot be factored in.

So don't assume the fundraise means there's is a deal or deals being worked on.

You're right D-Geeman...they have to prove they have enough funds to see them through the next 12 months...without this the Auditors can't sign off the accounts.

Sorry..correction:

If we're licencing out the pipeline then we could also patent protect at the point a potential licencee is showing real interest in that particular pipeline item and they want us to go ahead and patent it. It all depends on how much of our pipeline will be developed solely by Avacta or for a client...

If we're licencing out the pipeline then we patent protect at the point someone is showing real interest and wants us to go ahead a patent it that way they get the protection needed for a deal.

Many obviously agree with me and would like to thank you for your concern too...

You really should trot along now chaps so you can help other total strangers on other BB's by pointing out the errors of their ways...

We're all being led to believe society has become very selfish and it's all about me, me, me these days. Well! my faith has been restored based on so many people spending so much time out of their busy lives to come on here and show so much concern over our investment in this company. WOW! how kind of you all to spend so much time worrying about others , especially people you don't know, and their misguided expenditure when you could be spending the time enjoying life with your beloved family and friends. Thank you..

Now enough is enough and I think we have all noted your concerns and it's time for you to go and enjoy your life, especially since most of us really don't know how long we might have left of it...

Again many thanks for your concerns...bye bye...

The buys behind those sells have been going through all day it smaller tranches...

2 x 250000...and an end of day RNS...mmm...

Timing my dears, timing...

She's done a couple of Investor Meets for other companies recently...

There's definitely more of an American approach being introduced...CC perhaps...

Https://roycastle.org/remembering-steven-pilbeam/

Katie Pilbeam????

If the Agreement with Point Bio remains in place with adjustments to reflect the fact Lilly are now the new owners of Point then we have, in effect, a deal for PreCision with Lilly now...and Lilly, being who they are, I'm sure will be given access to our AVA6000 data if they express a serious interest in that too...

Anyone saying the PreCision platform has been overlooked yet again is misleading this BB...

Firstly, we already have a PreCision deal in place with Point Biopharma.

https://avacta.com/license-agreement-with-point-biopharma-inc/

Point Biopharma have just been acquired by Eli Lilly.

https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-point-biopharma

'Cryptophycin-52 (Cr-52, LY355703, 11) was designed by Eli Lilly, and its reported potency is 40- to 400-fold greater than that of paclitaxel or vinca alkaloids, making it a promising clinical candidate [111,112,113,114]. The mechanism of action involves suppressing microtubule dynamics and arresting cells in the G2/M phase. However, the co-crystallization data between Cr-52 and tubulin has not yet been solved, and the details of the binding site remain elusive. The Cr-52 structure is an analogue to cryptophycin-1, containing two hydroxy acids (units A and D) and two amino acids (units B and C). Due to the steric hindrance of the geminal dimethyl group, it is more resistant against ester hydrolysis than are cryptophycin-1 derivatives [103]. After numerous preclinical studies, Eli Lilly advanced Cr-52 to clinical trials, with aims to define the MTD, recommended dose, pattern of toxicity, and pharmacokinetic profile. Two Phase I clinical trials were performed, and a dose of 1.5 mg/m2 was recommended for Phase II evaluation on a day 1 and 8 schedule every 21 days [111].

Despite these findings, the treatment effect for NSCLC was not achieved as expected. Twenty-six patients were enrolled, of whom 25 were evaluable for toxicity and response. There were no responders when the weekly dose was lowered from 1.5 mg/m2 to 1.125 mg/m2. Median survival was 4.1 months, and toxicity was predominantly neurologic in the form of peripheral neuropathy and constipation [113]. Another study was performed to determine the activity of LY355703 and to characterize its toxicity profile in patients with platinum-resistant advanced ovarian cancer, but only modest activity was observed in these patients [114].

Cr-52 failed in Phase II clinical studies due to the lack of efficacy and its high toxicity at the chosen doses. Although the cryptophycins were unable to advance to stand-alone agents, desirable characteristics including high potency, relative hydrophilicity, lack of P-gp susceptibility, and a common resistance mechanism make it an attractive ADC payload. '

Now who'se to say Lilly might not be looking at PreCision???

Https://avacta.wistia.com/medias/1h18nhz59w

Great viewing...watch and learn...

And from the placing announcement RNS...note last item...FURTHER EXPAND PIPELINE'..you was told...😉 question is...are they picking them out of the hat themselves or have they been approached by one or more companies to use their products...

'pre|CISION? pre-clinical pipeline:

o Next clinical candidate to be selected Q1 2025;

o Tumour microenvironment activated drug conjugate clinical candidate to selected in the second half of 2025; and

o Further expand pipeline;'

From the AVA6000 update...

'The continuing validation of the pre|CISION? platform we are seeing in the clinic underlines our confidence in the significant opportunity to apply pre|CISION? to a range of warheads, including those much more potent than doxorubicin.'

Ipadtrader...nah..I think they are UK based...the UK is in Europe...just not in the EU.

👍